Lung Cancer News

Individuals diagnosed with cancer during incarceration or within a year after release from prison have a higher risk for cancer mortality than those never incarcerated, according to a study from Yale Cancer Center.

Joyce Ohm, PhD, has been named chair of cancer genetics and genomics at Roswell Park Comprehensive Cancer Center.

American Association for Cancer Research and ASCO have issued a joint policy statement delineating the latest scientific evidence on use of e-cigarettes and other electronic nicotine delivery systems.

Often regarded in oncology as a complementary diagnostic or early detection tool, liquid biopsy has moved into routine clinical use to help guide treatment decisions in the era of targeted, molecular-based therapies.

A novel anti-TIGIT antibody improved overall response rates and extended PFS when added to anti-PD-1 therapy and to anti-PD-1 therapy plus an adenosine receptor antagonist for patients with advanced, PD-L1-high non-small cell lung cancer.

Certain fungal species in tumors may be associated with worse cancer outcomes, according to a study conducted by researchers at Weill Cornell Medicine and Duke University and published in the journal Cell.

An increasing number of oral anticancer drugs have been granted FDA approval and introduced into clinical practice.

A randomized phase 3 trial that evaluated durvalumab vs. chemotherapy for treatment of certain patients with stage IV non-small cell lung cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer.

The addition of atezolizumab to bevacizumab showed promising efficacy among patients with nonsquamous non-small cell lung cancer with high tumor mutational burden, according to results of a phase 2 trial published in JAMA Oncology.

The FDA granted accelerated approval to adagrasib for certain adults with non-small cell lung cancer.